visit (Q143755)
From MaRDI portal
 | This is the item page for this Wikibase entity, intended for internal use and editing purposes. Please use this page instead for the normal view: visit |
Vaccine Phase I Design with Simultaneous Evaluation of Immunogenicity and Toxicity
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | visit |
Vaccine Phase I Design with Simultaneous Evaluation of Immunogenicity and Toxicity |
Statements
9 August 2023
0 references
Phase I clinical trials are the first step in drug development to test a new drug or drug combination on humans. Typical designs of Phase I trials use toxicity as the primary endpoint and aim to find the maximum tolerable dosage. However, these designs are poorly applicable for the development of cancer therapeutic vaccines because the expected safety concerns for these vaccines are not as much as cytotoxic agents. The primary objectives of a cancer therapeutic vaccine phase I trial thus often include determining whether the vaccine shows biologic activity and the minimum dose necessary to achieve a full immune or even clinical response. This package implements a Bayesian Phase I cancer vaccine trial design that allows simultaneous evaluation of safety and immunogenicity outcomes. See Wang et al. (2019) <doi:10.1002/sim.8021> for further details.
0 references
